Next-Generation Biomanufacturing Market worth $43.16 Billion by 2030 - Exclusive Report by InsightAce Analytic
14 Jun 2022
AntibodyCell TherapyVaccineAcquisitionCollaborate
JERSEY CITY, N.J., June 14, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "
"
Global Next-Generation Biomanufacturing Market
(Medical Applications (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, And Other Applications), Products (Continuous Upstream Biomanufacturing Products, Single-Use Upstream Biomanufacturing Products, And Downstream Biomanufacturing Products), Workflow (Upstream And Downstream Biomanufacturing), End-User (Biopharmaceutical Companies, CMOs (Contract Manufacturing Organizations)/CDMOS (Contract Development And Manufacturing Organization), And Research Institutions))- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
According to the latest research by InsightAce Analytic, the global next-generation biomanufacturing market is valued at US$ 19.85 Billion in 2021, and it is expected to reach US$ 43.16 Billion by 2030, with a CAGR of 9.3% during the forecast period of 2022-2030.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1261
Next-generation biomanufacturing services allow the development and manufacturing of a wide range of products with the highest level of quality than the first generation biomanufacturing products. These services focus on single-use technologies such as single-use bio-containers and single-use bioreactors, enabling better process flexibility and efficiency.
Factors such as the advanced medical technologies, high demand for gene and cell therapy products, rising effects by the government to develop more efficient next-generation bioprocessing units, high prevalence of chronic & genetic diseases, increasing geriatric population, growing awareness among the people regarding the benefits of the next-generation bio-manufacturing, availability of well-established healthcare infrastructures are projected to witness significant growth of the market during the forecast years. The development and production of drugs and materials include complex procedures and require special equipment. Hence, to handle such difficulties, biopharmaceutical companies opt for advanced biomanufacturing solutions to increase production quality and efficiency, which is expected to enhance the production of next-generation biomanufacturing products in the upcoming years.
On the other side, factors such as the lack of skilled professionals and the complexity of the process operations may restrain the market adoption over the forecast period.
Regionally, North America dominated this market in 2021 and is expected to lead the next-generation biomanufacturing market over the forecast period (2022-2030), owing to the well-developed biopharmaceutical industries, fast adoption of modern technologies, and the rising usage of innovative technologies.
Enquire Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1261
Key market players operating in the next-generation biomanufacturing market include Applikon Biotechnology BV (Netherlands), bbi-biotech GmbH (Germany), Danaher Corporation (US), Eppendorf AG (Germany), Esco Group of Companies (US), GEA Group Aktiengesellschaft (Germany), Meissner Filtration Products, Inc. (US), Merck KGaA (Germany), PBS Biotech, Inc. (US), Pierre Guérin (France), Sartorius AG (Germany), Shanghai Bailun Biotechnology Co. Ltd. (China), Solaris Biotechnology Srl. (Italy), Thermo Fisher Scientific Inc. (US), ZETA GmbH (Austria), among others.
Key developments in the market:
In August 2021, PBS Biotech (US) secured its highest funding round with BroadOak Capital Partners to grow its product offerings and capabilities. The budget is used to expand PBS's product offerings and abilities and meet the demand for cell therapies.
In February 2021, Merck (Germany) partnered with Alteogen, Inc. (South Korea), a company providing late-stage CDMO services through Merck's BioReliance end-to-end solutions. Alteogen selected Merck to develop and produce recombinant biologics for developing and clinically evaluating next-generation therapeutics of monoclonal antibody drugs.
In November 2020, Merck (Germany) collaborated with Transcenta, a biotherapeutics company, to implement & advance continuous manufacturing for protein therapeutics.
Market Segments
Global Next-Generation Biomanufacturing Market, by
Medical Applications, 2022-2030(Value US$ Bn)
Monoclonal Antibodies
Hormones
Vaccines
Other Applications
Global Next-Generation Biomanufacturing Market, by
Products, 2022-2030(Value US$ Bn)
Continuous Upstream Biomanufacturing Products
Single-Use Upstream Biomanufacturing Products
Downstream Biomanufacturing Products
Global Next-Generation Biomanufacturing Market, by
Workflow, 2022-2030(Value US$ Bn)
Downstream Biomanufacturing
Global Next-Generation Biomanufacturing Market, by
End-Users, 2022-2030(Value US$ Bn)
Biopharmaceutical Companies
CMOs (Contract manufacturing organizations)/CDMOs (Contract Development and Manufacturing Organization)
Global Next-Generation Biomanufacturing Market, by
Region, 2022-2030(Value US$ Bn)
North America
Europe
Latin America
Middle East & Africa
North America Next-Generation Biomanufacturing Market, by
Country, 2022-2030(Value US$ Bn)
U.S.
Canada
Europe Next-Generation Biomanufacturing Market, by
Country, 2022-2030(Value US$ Bn)
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific Next-Generation Biomanufacturing Market, by
Country, 2022-2030(Value US$ Bn)
India
China
Japan
South Korea
Australia & New Zealand
Latin America Next-Generation Biomanufacturing Market, by
Country, 2022-2030(Value US$ Bn)
Brazil
Mexico
Rest of Latin America
Middle East & Africa Next-Generation Biomanufacturing Market, by
Country, 2022-2030(Value US$ Bn)
GCC Countries
South Africa
Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global next-generation biomanufacturing market
To receive an industry overview and future trends of the next-generation biomanufacturing market
To analyze the next-generation biomanufacturing market drivers and challenges
To get information on the next-generation biomanufacturing market size (Value US$ Bn) forecast to 2030
Significant investments, mergers & acquisitions in the next-generation biomanufacturing market industry
For Customization @
https://www.insightaceanalytic.com/customisation/1261
Other Related Reports Published by InsightAce Analytic:
Global iPSCs Manufacturing Services Market
Global Biopharmaceutical Excipient Manufacturing Market
Global Allogeneic Cell Therapy Manufacturing Market
Global mRNA Synthesis and Manufacturing Services Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
SOURCE InsightAce Analytic Pvt. Ltd.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.